导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 9.82% | 840/4773 |
| 近一周 | -3.13% | 4579/5465 |
| 近一月 | -1.88% | 1356/5421 |
| 近一季 | -9.16% | 3508/5231 |
| 近半年 | -2.82% | 2292/4920 |
| 近一年 | 23.96% | 358/4394 |
| 近两年 | 80.77% | 838/2954 |
| 近三年 | 71.22% | 335/2253 |
| 成立以来 | 24.85% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
7.05% 210/4961 |
10.90% 2387/5312 |
- - |
- - |
| 2025 | 40.70% 763/4813 |
-4.57% 3203/3635 |
3.05% 1184/4076 |
31.46% 1119/4524 |
8.84% 216/4813 |
| 2024 | 21.37% 414/3463 |
12.79% 22/2808 |
4.74% 201/3014 |
7.98% 2783/3129 |
-4.85% 2500/3463 |
| 2023 | -4.43% 677/2656 |
8.68% 450/2280 |
0.94% 264/2385 |
-4.76% 1217/2515 |
-8.53% 2296/2655 |
| 2022 | -12.10% 270/2207 |
-10.73% 413/1919 |
5.88% 810/2016 |
-8.83% 228/2113 |
2.01% 1064/2208 |
| 2021 | 32.78% 55/1822 |
8.39% 65/1255 |
5.41% 812/1330 |
19.54% 50/1466 |
-2.78% 1417/1822 |
| 2020 | 16.66% 773/1250 |
-10.06% 744/1028 |
3.33% 942/1067 |
11.12% 477/1164 |
12.97% 405/1184 |
| 2019 | 20.46% 665/1092 |
23.21% 561/754 |
-4.60% 433/804 |
-4.00% 754/850 |
6.76% 554/918 |
| 2018 | -23.16% 271/834 |
- - |
- - |
- - |
-9.80% 162/691 |
| 2017 | 2.54% 441/714 |
- - |
- - |
- - |
- - |
| 2016 | -12.24% 300/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 安信中证一带一路主题指数 VS. 长安沪深300非周期A(740101) |